Inicio
Markets
Charts & Ideas
Algo
Noticias
Store
Corredores
Descargar
Calendario económico
Señales Comerciales
WebTerminal
Pulse
/
para buscar: @user, $symbol, ...
Buscar
Entrada
Crear una cuenta
Español
English
Русский
中文
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
NVCT
#3038
Nuvectis Pharma, Inc. Common Stock
8.8
6
-0.78%
Sector:
Básica:
Profit Currency:
Rango diario
Rango anual
Cambio diario
-0.78%
Monthly Change
+0.68%
6 month change
+32.24%
Cambio anual
+27.85%
Cierres anteriores
8.9
3
Open
8.8
6
Bid
Ask
Low
8.8
6
High
8.8
6
Volumen
17
Markets
Acciones
Atención Sanitaria
NVCT
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
14.75 M
17.77 M
23.39 M
26.49 M
—
Valuation ratios
Enterprise value
90.64 M
128.2 M
108.05 M
168.41 M
651.59 M
Price to earnings ratio
-4.97
-5.8
-4.87
-5.72
-25.14
Price to sales ratio
—
—
—
—
—
Price to cash flow ratio
7
8.08
7.56
10.29
44.81
Price to book ratio
6.68
10.57
9.53
8.94
16.39
Enterprise value to EBITDA ratio
—
—
—
—
—
Profitability ratios
Return on assets %
0.94
1.16
1.02
0.83
0.85
Return on equity %
1.34
1.82
1.96
1.44
1.34
Return on invested capital %
—
—
—
—
—
Gross margin %
—
—
—
—
—
Operating margin %
—
—
—
—
—
EBITDA margin %
—
—
—
—
—
Net margin %
—
—
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
Current ratio
3.3
2.75
2.09
2.38
11.4
Inventory turnover
—
—
—
—
—
Asset turnover
—
—
—
—
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
Per share metrics
Operating cash flow per share
1.07
1.03
0.72
0.73
0.75
EBIT per share
—
—
—
—
—
EBITDA per share
—
—
—
—
—
Total debt per share
—
—
—
—
—
Cash per share
1.58
1.23
1.08
1.45
5.76
Net current asset value per share
1.61
1.23
1.09
1.45
5.8
Tangible book value per share
1.12
0.78
0.57
0.84
3.74
Working capital per share
1.12
0.78
0.57
0.84
3.74
Book value per share
1.12
0.78
0.57
0.84
3.74
Noticias
Nuvectis inicia ensayo fase 1b combinando NXP900 con osimertinib
Nuvectis inicia ensayo fase 1b combinando NXP900 con osimertinib
Nuvectis initiates phase 1b trial combining NXP900 with osimertinib
H.C. Wainwright reitera calificación de Compra para Nuvectis Pharma
Nuvectis Pharma stock rating reiterated at Buy by H.C. Wainwright
Kaplan compra acciones de Nuvectis Pharma (NVCT) por valor de $64,240
Presidente de Nuvectis Pharma compra acciones por $28,600
Director de Nuvectis Pharma, Sánchez, compra acciones NVCT por $75k
H.C. Wainwright reitera calificación de Compra para Nuvectis Pharma con objetivo de 10 dólares
H.C. Wainwright mantiene calificación de Compra para Nuvectis Pharma con objetivo de $10
H.C. Wainwright reiterates Buy rating on Nuvectis Pharma stock at $10 target
Nuvectis Pharma incorpora a ex ejecutivo de Intra-Cellular a su junta directiva